Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Protagonist Therapeutics has scheduled a conference call and webcast for November 21st at 4:30 pm ET to announce their new oral peptide IL-17 antagonist development candidate. During the presentation, the company will share in vitro and pre-clinical proof-of-concept study results.
US investors can dial 1-877-407-0752, while international investors can access the call at 1-201-389-0912 using Conference ID 13750274. The webcast will be available through a provided link, and a replay will be accessible on the Company's Investor Relations Events and Presentations webpage after the event.
Protagonist Therapeutics ha programmato una conference call e un webcast per il 21 novembre alle 16:30 ET per annunciare il loro nuovo candidato allo sviluppo di antagonisti orali del peptide IL-17. Durante la presentazione, l'azienda condividerà i risultati di studi di prova di concetto in vitro e preclinici.
Gli investitori statunitensi possono chiamare il numero 1-877-407-0752, mentre gli investitori internazionali possono accedere alla chiamata al numero 1-201-389-0912 utilizzando l'ID conferenza 13750274. Il webcast sarà disponibile tramite un link fornito, e una registrazione sarà accessibile sulla pagina degli Eventi e Presentazioni delle Relazioni con gli Investitori dell'azienda dopo l'evento.
Protagonist Therapeutics ha programado una llamada de conferencia y un webcast para el 21 de noviembre a las 4:30 p.m. ET para anunciar su nuevo candidato al desarrollo de antagonistas orales del péptido IL-17. Durante la presentación, la empresa compartirá los resultados de estudios in vitro y preclínicos de prueba de concepto.
Los inversores estadounidenses pueden marcar el 1-877-407-0752, mientras que los inversores internacionales pueden acceder a la llamada al 1-201-389-0912 utilizando el ID de Conferencia 13750274. El webcast estará disponible a través de un enlace proporcionado, y una repetición estará accesible en la página de Eventos y Presentaciones de Relaciones con Inversores de la Compañía después del evento.
프로타고니스트 테라퓨틱스는 11월 21일 오후 4시 30분 ET에 새로운 경구용 펩타이드 IL-17 길항제 개발 후보를 발표하기 위해 컨퍼런스 콜과 웹캐스트를 예정하고 있습니다. 발표 중에 회사는 시험관 내 및 비임상 개념 증명 연구 결과를 공유할 것입니다.
미국 투자자는 1-877-407-0752로 전화할 수 있으며, 국제 투자자는 회의 ID 13750274를 사용하여 1-201-389-0912로 접속할 수 있습니다. 웹캐스트는 제공된 링크를 통해 이용할 수 있으며, 이벤트 후에는 회사의 투자자 관계 이벤트 및 프레젠테이션 웹페이지에서 다시 볼 수 있습니다.
Protagonist Therapeutics a programmé une conférence téléphonique et un webcast pour le 21 novembre à 16h30 ET afin d'annoncer leur nouveau candidat de développement d'antagonistes oraux du peptide IL-17. Au cours de la présentation, l'entreprise partagera les résultats d'études de preuve de concept in vitro et précliniques.
Les investisseurs américains peuvent composer le 1-877-407-0752, tandis que les investisseurs internationaux peuvent accéder à l'appel au 1-201-389-0912 en utilisant l'ID de conférence 13750274. Le webcast sera disponible via un lien fourni, et une rediffusion sera accessible sur la page Événements et Présentations des Relations Investisseurs de la société après l'événement.
Protagonist Therapeutics hat eine Telefonkonferenz und einen Webcast für den 21. November um 16:30 Uhr ET angesetzt, um ihren neuen Entwicklungskandidaten für orale Peptid-IL-17-Antagonisten anzukündigen. Während der Präsentation wird das Unternehmen die in vitro und präklinischen Machbarkeitsstudien Ergebnisse teilen.
US-Investoren können die Nummer 1-877-407-0752 wählen, während internationale Investoren zum Anruf unter 1-201-389-0912 mit der Konferenz-ID 13750274 zugreifen können. Der Webcast wird über einen bereitgestellten Link verfügbar sein, und eine Wiederholung wird nach der Veranstaltung auf der Seite für Investorenbeziehungen der Firma für Veranstaltungen und Präsentationen zugänglich sein.
- None.
- None.
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below
NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results.
Conference Call and Webcast Details
The dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are:
US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13750274
The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1698744&tp_key=f6482f31c0
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
About Protagonist
Protagonist Therapeutics is a late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (JNJ-2113, formerly PN-235), is the first targeted oral peptide designed to selectively block the IL-23 receptor,which underpins the inflammatory response in moderate-to-severe plaque PsO and other IL-23-mediated diseases. Icotrokinra binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells. Icotrokinra is licensed to Johnson & Johnson and is currently in Phase 3 development for psoriasis and is nearing completion of Phase 2b development for ulcerative colitis. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera. Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17, hepcidin mimetic, and anti-obesity programs.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics
View the original press release on accesswire.com
FAQ
When is Protagonist Therapeutics (PTGX) announcing their IL-17 antagonist candidate?
What will be presented in Protagonist Therapeutics' (PTGX) upcoming conference call?
How can investors access Protagonist Therapeutics' (PTGX) November 21st conference call?
Will there be a replay available for Protagonist Therapeutics' (PTGX) IL-17 announcement?
